Moffitt in the News - Media Coverage of Moffitt Cancer Center

Where You Are:

September 4-11, 2014

 

Diagnosis: Early warning system
Nature – Sept. 11

A successful screening programme relies on first-rate interpretation of results. Robert Gillies, chairman of cancer imaging at the Moffitt Cancer Center in Tampa, Florida, says that current interpretive methods, no matter how they classify the nodules, are not gleaning as much detailed information from the CT images as they could. 

Hillsborough committee approves $200,000 in innovation grants
The Tampa Tribune – Sept. 11

Moffitt Cancer Center requested and received $12,300 for its Business of Biotech Conference 2015. The conference includes those attempting to start tech companies as well as venture capitalists and angel investors looking to buy in to those ideas.

Save the date: Tampa-Hillsborough 2014-15 society datebook
Tampa Bay Times – Sept. 11

April 18: Twenty-second annual Magnolia Ball, benefits Moffitt Cancer Center; 5:30 p.m.; A La Carte Event Pavilion; $1,000; black tie; (813) 745-4860 or MOFFITT.org/MagnoliaBall.

First six inducted into Florida Inventors Hall of Fame
Tampa Bay Times – Sept. 10

A shoutout also goes to the Hall of Fame advisory board. It's a who's who from Florida's most dynamic organizations — SRI Research, Moffitt Cancer Center, All Children's Hospital Johns Hopkins Medicine, Draper Lab, the Florida Institute for Human & Machine Cognition, and many others.

New group to help patients with all forms of cancer, caregivers
The Tampa Tribune – Sept. 10

Susan Scherer, CEO of RN Cancer Guides, will be this week’s guest speaker. Scherer, who also works with Moffitt Cancer Center patients, will present specific ideas on how to bring peace of mind into the home going forward with the disease. 

Chamber’s top citizen places value in giving
The Tampa Tribune – Sept. 10

Anita has been at the forefront of organizing several large fundraising events as well as small gatherings such as craft parties for Moffitt Cancer Center patients staying at Hope Lodge, an American Cancer Society facility located on the University of South Florida campus. 

Brain Cancer Vaccine Trial Starts
Bay News 9 – Sept. 9

Moffitt Cancer Center offered a free clinical trial for glioblastoma patients.

Strategies for the Detection of Recurrent Melanoma
OncLive – Sept. 9

Jeffrey S. Weber, MD, PhD, Director, Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center and Research Institute

Conducting Innovative Public Health Prevention Research
Orlando Medical News – Sept. 9

“This will be our first time for the center to work very closely with research colleagues at Moffitt Cancer Center, and state, regional and local partners, including the state health department, American Cancer Society, and many other community-based organizations in Tampa Bay’s tri-county region,” said Bryant.

UPDATED WITH VIDEO: FDA OKs Keytruda, the First PD-1 Blocker for Advanced Melanoma
Plastic Surgery Practice – Sept. 7

Jeffery S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at Moffitt Cancer Center, and one of the lead investigators of the PD-1 clinical trial which led to the drug receiving breakthrough status from the FDA spoke with PSP about the new approval and what it means for patients with melanoma. “It’s an excellent drug,” he says. “It’s easy to tolerate and easy to give.”

Proposed 1-cent sales tax hike in Polk spawning debate
Bay News 9 – Sept. 7

That would include more bus routes to places, including Disney Word and the Orlando and Tampa airports, Moffitt Cancer Center and the James A. Haley Veterans Hospital.

Moffitt has new department chief
The Tampa Tribune – Sept. 7

Louis B. Harrison has joined Moffitt Cancer Center as chairman of the Department of Radiation Oncology, and Senior Member.

FDA approves Keytruda for advanced melanoma
Formulary Watch – Sept. 5

“This drug will be used frequently in metastatic melanoma patients,” according to Geoffrey Gibney, MD, a medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center.

FDA Approves New Melanoma Drug
WTSP, 10 News – Sept. 5

The doctor in charge of Moffitt Cancer Center’s melanoma research is one of the lead investigators in a clinical trial of Keytruda.

For sailboat designer Charley Morgan, life’s still a breeze
Tampa Bay Times – Sept. 5

At the University of South Florida’s Moffitt Cancer Center, he got an answer. There was a tumor on a kidney. 

Dine at St. Augustine restaurant, support Northeast Florida nonprofits
The Florida Times-Union “Beth Cravey’s blog” – Sept. 5

Other participating charities for the St. Augustine location are the Betty Griffin House, Boy Scouts Of America, Community Hospice of Northeast Florida, Florida School for the Deaf and the Blind, Friends of the Library, Laundry Project, Make-A-Wish Foundation, Moffitt Cancer Center, St. Augustine Humane Society, St. Gerard Campus, St. Johns County Council on Aging, Take Stock in Children and WORC Inc.

FDA Okays First PD Inhibitor: Pembrolizumab for Melanoma
Medscape – Sept. 4

One of the lead investigators of the PD-1 clinical trial, Jeffrey S. Weber, MD, PhD, director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at the Moffitt Cancer Center in Tampa, Florida, commented in a statement: “Pembrolizumab is the first PD-1 drug to be approved by the FDA, and it is a clearly effective drug that will prolong survival for many patients with metastatic melanoma. This approval is a real advance, and a major milestone in the treatment of the disease.”

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories. 

Please click here to view news releases featuring the cancer center.

 
 
 
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions